Posted on

* Man with incurable cancer looks to complete quest to run marathons in all 50 states

Man with incurable cancer looks to complete quest to run marathons in all 50 states

Reported by: Olena Heu

When you are asked to buy Norvasc, make sure that you drink the medication according to the instructions levitra without prescription you are consuming the nitrate drugs in order to treat your chest pain or heart related worries. Your servings should be a viagra wholesale uk cup and 4 ounces of juice. free get viagra Physical problems, such as nerve damage, are one cause. It causes tadalafil generic cheapest learningworksca.org pains, gas, bloating, heartburn, diarrhea, and internal toxicity.


Click here to read the full article and see the video

One of the participants in Sunday’s Honolulu Marathon has overcome many obstacles to get here. The Minnesota resident was diagnosed with an incurable cancer.

Don Wright, 71, says he loves to run.

“I feel like I am floating past the scenery and just gliding along watching it go by,” Wright said.

Nearly 10 years ago, just days after Don’s first marathon, he was diagnosed with myeloma, which is a cancer of the blood.

“The diagnosis for my cancer was a three-to-five year median survival,” Wright said.

Inspired not to let the disease keep him down, the Minnesota resident decided to keep running.

“My family and I have been running marathons in every state. That’s been our goal and now we’ve run marathons in 49 of the 50 states,” Wright said.

When he completes the Honolulu Marathon on Sunday Don will achieve his goal of running 50 marathons in all 50 states…in the 50th state.

“It feels like when I am running along in a marathon like I have just stuck my finger right in that cancer’s eye,” Wright said.

Don runs with the hope of raising funds and awareness for The Tackle Cancer Foundation and has been able to control his battle with cancer thanks to a drug currently being used in clinical trials for his condition.

“That has kept it stable for five years and I actually feel very good,” Wright said.

Will this be his last marathon?

“This will never, no, no I will keep running marathons until I can’t, and that’s hopefully a long way off,” Wright said.

Click HERE to view Wright’s running blog.

Posted on

ALS patient is living his second miracle

http://www.crainsdetroit.com/article/20121130/BLOG007/121139991/als-patient-is-living-his-second-miracle

ALS patient is living his second miracle

Follow-up stem-cell operation has more amazing results

November 30, 2012

ALS patient is living his second miracle

Follow-up stem-cell operation has more amazing results

Emory University Hospital
Doctors inject stem cells into ALS patient

The treatment depends on the severity of the problem. viagra sales in canada Which One Is Better? One thing worth mentioning is that tadalafil online no prescription consuming the same dose and quantity of Kamagra tablets let these patients take a sigh of relief. This will help them to gauge the concerns of the parents for their child and downtownsault.org levitra uk also the goals and objectives they would like to put into practice immediately using your own car. OAE tests is basically a screening test, it by no means should be interpreted as a confirmatory test. http://downtownsault.org/black-dragon-grand-opening/ levitra without prescription
Ted Harada is living his second miracle right now, savoring every minute of every hour of it for as long as it lasts. His strength is back up, there’s a spring in his step, he’s got a strong grip back in his hands, and the symptoms of his ALS once again are in retreat to the ongoing surprise of his doctors and to the delight of his family.

Once again, Harada is easily going up the stairs to tuck his kids in at night and give them a kiss, instead of struggling up a step at a time, having to hold onto the handrail for support. Once again, he knows — or is as close to knowing as you can with such a disease — that he is part of something that will eventually change the death-sentence prognosis that until now has been a certainty as soon as there is a diagnosis with the dreaded words no one wants to hear: amyotrophic lateral sclerosis — Lou Gehrig’s disease.

“The first time, it’s easy to say it was an outlier. Luck. But I’ve been helped twice. Twice, and you can throw luck out the window. They’ve got to figure out, now, what’s going on with me,” he says. “We’ve got to turn Lou Gehrig’s disease into Lou Gehrig’s chronic illness.”

Some background: I interviewed Harada by phone in early October for a package of stories Crain’s ran Oct. 29 about successful Phase 1 human trials that University of Michigan and Emory University physicians and researchers had recently concluded in Atlanta, injecting stem cells into the spinal column of ALS patients.

Because Phase 1 trials are designed to test safety before any approval from the Food and Drug Administration to move on to Phase 2 trials, which test efficacy, researchers are cautious. They generally decline much comment for fear about running afoul of the bureaucrats.

But patients themselves are free to talk to anyone they want, and Harada was eager to tell his tale.

Ted Harada

 

Harada, 40, is a former manager at FedEx who first noticed symptoms of ALS in 2009 while playing Marco Polo with his kids in the family swimming pool.

On March 9, 2011, he got an injection of 500,000 stem cells — the cells were derived by Rockville, Md.-based Neuralstem Inc. after a patient donated spinal-cord tissue in 2002 — as part of an 18-operation, 15-patient trial that last 2½ years.

The operations were conducted by Emory University Hospital physician Dr. Nicholas Boulis. The trial was designed, in part, by Dr. Eva Feldman, director of the A. Alfred Taubman Medical Research Institute at UM and director of the ALS clinic at the University of Michigan Health System. Boulis is a former colleague of hers at UM.

Harada was one of three patients who got two rounds of injections, the second this past Aug. 22. Researchers monitored all patients for side effects, of course, and the trials proved to be remarkably safe. The results were presented by Feldman in October at the annual meeting of the American Neurological Association in Boston.

Researchers also do a variety of tests on patients to look for signs of efficacy, too, to give them an idea of what they might expect should they get to Phase 2. Some patients showed little or no improvement. Others had modest gains.

Harada was off the charts.

When I interviewed Harada, he was feeling punk from fighting off a lingering staph infection and thought he was starting to see an improvement in symptoms as a result of the injection of cells Aug. 22. Because of the infection, it was hard to tell, and researchers at Emory hadn’t begun doing follow-up tests with him.

University of Michigan
Eva Feldman

 

But there was no equivocation about the miracle that had happened after Harada’s first injection.

Two weeks after the operation, Harada thought he was feeling stronger, that there had been an improvement in his overall health. But he was afraid he was imagining things. That it was wishful thinking. Or a placebo effect.

Before the operation, Harada could barely limp with the help of canes or handrails up the steps to say goodnight to his kids at his home in McDonough, Ga. If he sat in a chair and his wife put the least bit of resistance on the top of his knee, he couldn’t budge his leg off the ground.

Harada didn’t wait for the doctors to test him.

“I asked my wife to come over and give me a test,” he told me in October.

She braced her hand against the top of his knee, as she had done many times. This time, though, his foot didn’t stay planted on the ground. It went up in the air.

They tried it, again. She pushed harder. He lifted his leg. A third time, his wife really pressing down her hand.

He lifted his leg.

She pushed down with two hands. He lifted his leg. “It was shock. ‘Is this real? This isn’t supposed to happen,’ ” Harada recounted to me.

He called the folks at Emory to tell them the news. He doesn’t blame them for what happened next. They tried to temper his enthusiasm. They explained the power of placebo effects.

“I know what a placebo effect is. I’m not crazy. This isn’t a placebo effect,” Harada responded.

“If anyone was more surprised than me, it might have been my doctors,” he told me.

Subsequent tests showed emphatically that what was going on — the mechanism of which is still not understood — was clearly not a placebo. Across a range of tests, there was demonstrative, clear, seemingly miraculous improvement.

“Every night I went to bed worried I’d wake up and it would be gone, that I’d have made the whole thing up,” he said. And every day for two or three months, not only did he wake up and hadn’t made the whole thing up, he woke up stronger than when he went to bed.

“I continued to improve in quantum leaps,” he said.

About a year after the operation, Harada began to notice a gradual decline, a decline that continued until his second operation — though he was still stronger when he went into the second operation than he had been going into the first.

When I talked to him in October, Harada was pretty sure he was feeling a little better but was tempering his expectations. “It would have been greedy to expect such good results, again,” he said.

Today, though, his staph infection has been cleared up, and there’s empirical evidence another miracle is taking place.

“I’m definitely getting stronger, there’s no doubt. Tests are showing beyond a doubt I’ve gained strength again,” Harada said. “I have more energy. My legs don’t get tired as quickly as they did. My hands have gotten stronger, again.”

By Oct. 20, Harada was feeling strong enough that he took part in a 2.5-mile fundraising ALS walk in Atlanta.

“If the walk had been in July, I wouldn’t have attempted it,” he said. “After a third of a mile, I would have been done. I would have sat down and said, ‘Someone come pick me up in a car.’ ”

Harada did the 2.5 miles, no problem, still going strong when he hit the finish line.

Harada said one researcher told him after putting him through his tests on a visit earlier this month that, in Harada’s words: ” ‘If I hadn’t seen it with my own eyes, I wouldn’t believe it. If I was at another hospital and reading reports about you, I’d say it had to be B.S.’

“I’ve been blessed beyond belief,” he said.

Harada still has ALS. He still knows the likely prognosis is death. For him. But based on what has happened to him, there’s hope the prognosis of death won’t always accompany the diagnosis. Not now, not that there’s clearly some possible mechanism for improvement, something researchers need to understand and refine.

Feldman is awaiting approval from the FDA for a Phase 1B trial that she hopes will begin soon in Ann Arbor. It involves injecting three patients with 1 million stem cells, double the dose of the first trials.

If there are no ill effects from doubling the amount of stem cells, a Phase 2 study of 32 patients could begin next summer.

It’s worth repeating Harada’s words: “We’ve got to turn Lou Gehrig’s disease into Lou Gehrig’s chronic illness.”

Based on what’s happened, and what is happening, with Harada, that no longer seems like wishful thinking.

 

 

 

 

 

 

Posted on

Advancing on ALS

Eva Feldman

http://www.crainsdetroit.com/article/20121028/SUB01/310289962/advancing-on-als

October 28, 2012 8:00 PM

Advancing on ALS

Stem cell research nears next phase; trials may come to Ann Arbor
By Tom Henderson

Eva Feldman
Eva Feldman, director of the A. Alfred Taubman Medical Research Institute at the University of Michigan and director of the ALS clinic at the UM Health System

Approval by the U.S. Food and Drug Administration is expected any day for researchers and physicians at the University of Michigan to begin a second round of Phase 1 stem cell trials on patients with amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease.

ALS is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement. It usually leads to death within three to five years. Currently, there is no cure.

The first round of Phase 1 trials, which lasted 21/2 years and concluded Aug. 22, involved 18 operations that injected stem cells into the spines of 15 patients, three of whom were injected twice. The operations were conducted at Emory University Hospital in Atlanta by Nicholas Boulis, M.D.

Eva Feldman, M.D., director of the A. Alfred Taubman Medical Research Institute at UM and director of the ALS clinic at the University of Michigan Health System, helped design the study. Boulis is one of her former colleagues at UM.

The first study was to test safety only. and it passed with flying colors, according to a report Feldman issued this month at the annual meeting of the American Neurological Association in Boston, held in cooperation with the British Association of Neurologists. Feldman is president of the American group.

Four of the study patients died, three from ALS complications and one from a heart problem. But no safety issues arose from the study itself.

“It went better than I anticipated and could have ever hoped for,” Feldman said of the Phase 1 trial. “There were no adverse affects.”

The Phase 1B trial, which could begin as early as December, will involve injecting just three patients and will be conducted, pending FDA approval to move the trials to Ann Arbor from Atlanta, by Parag Patil, a UM physician.

The first trial involved injections of 500,000 stem cells. This trial will inject at least 1 million cells. The trials use a stem sell line derived at Rockville, Md.-based Neuralstem Inc. after a a patient donated spinal cord tissue in 2002.

If there are no ill effects from doubling the amount of stem cells, a Phase 2 study of 32 patients to test efficacy could start as early as next summer.

“It’s really exciting to bring this back to Michigan,” Feldman said. “The climate now for this is very embracing — not just in the state but in the university, too.”

Feldman was referring to the contentious climate for stem cell research in Michigan that culminated in voters’ approving embryonic stem cell research in 2008. One reason that the first trial was in Atlanta and not Ann Arbor was that all stem cell work got tarred with the same brush, she said.
Kamagra oral jelly is a famous medicine to relive erectile dysfunction quickly and simply. generic no prescription viagra Maran Nagarajan, CEO of Kaar envisions building an organization with a foundation of strong ethical practice, and a growth with commitment to social causes. http://raindogscine.com/?attachment_id=561 viagra samples Surveys that were carried out worldwide have got the results as nearly 57% of the raindogscine.com viagra cialis men all over the world. If you feel that you’re forking out substantial rates for medicines at the local pharmacy, then it is for certain that they are driving with the erectile disappointment difficulties. cialis no prescription canada
Although Feldman’s trials didn’t use embryonic stem cells, it was thought that Atlanta was a better place to start them. “I used to get these letters and emails against what we were doing,” she said, “but that’s stopped.”

Feldman said that while the primary purpose of the Phase 1B trial will be to test safety, it has been designed to test efficacy, too.

One post-surgery test on the three patients will use ultrasound to evaluate the movement of the patients’ diaphragm. Other tests will investigate how forcefully patients can expel their breaths and how much oxygen they can inhale.

“One of the purposes of the injections is to protect the large nerve cells that control breathing,” Feldman said. An inability to breathe is what ultimately kills many ALS patients.

Based on anecdotal evidence of improvements in some patients in the first round of safety tests (see story, Page 11), Feldman expects to see dramatic results in at least some patients — if not in the upcoming three-patient trials, then in the Phase 2 trials to follow.

The exact mechanism behind why stem cells helped rats and pigs in animal studies and now seem to have helped some patients is unclear. Feldman theorizes that the cells turn on repair signals inside the body, act as nursemaids for the damaged cells and slow, if not halt, the progression of the disease.

“This was something that had never been done before, and there was a lot of skepticism in the medical community — and ‘skepticism’ is a pretty polite word,” Feldman said of a procedure to inject stem cells into the spine of patients.

“Now that we’ve taken this idea and not only shown it’s feasible but safe, it’s opened up doors.”

In July, Clive Svendsen, Ph.D., director of the Cedars-Sinai Regenerative Medicine Institute in Los Angeles, was awarded an $18 million grant from the California Stem Cell Agency to do a Phase 2A study of 18 patients patterned after the UM-Emory study, using a stem cell line he derived.

The study, designed to test both safety and efficacy, will be done at three sites, including six operations by Boulis at Emory.

Svendsen, with Boulis, had begun work on the line in 2003 at the University of Wisconsin before Boulis’ partnership with Feldman. Troubles with that line, which included a drug that was genetically engineered into the stem cells, took years to surmount.

Svendsen’s stem cells are engineered to use a drug called glial-derived neurotrophic factor, a growth factor designed to help protect neurons from the effects of ALS.

Feldman is optimistic that Phase 2 trials on ALS patients will be so successful that she will be able to get funding and gain FDA approval to begin similar stem cell trials on patients with Alzheimer’s disease. She has been working on a grant from the National Institutes of Health to fund an Alzheimer’s study.

“We shouldn’t limit this technology to one disease,” Feldman said.

In part, that’s because there is a far larger population of Alzheimer’s patients than ALS patients, and in part because the brain can be injected with far more stem cells than can the spinal cord.

As a result, trials should be easier to conduct and therapies easier to devise.

Said Feldman: “Alzheimer’s is going to be easier than ALS.”

Posted on

* 50-state marathon runner stops in N.M.

50-state marathon runner stops in N.M.

http://www.koat.com/news/new-mexico/albuquerque/Marathon-Man/-/9153728/17072524/-/4xbrdv/-/index.html

Despite incurable cancer, man runs in dozens of marathons
Published 10:02 AM MDT Oct 21, 2012
ALBUQUERQUE, N.M. –
A Minnesota man diagnosed with an incurable form of cancer is on the run of his life as tries to run 50 marathons in 50 states.

Action 7 News reporter Tanya Mendis spoke with Don Wright on Sunday about his drive to keep running no matter what.

Wright said he was diagnosed with myeloma at 62. Nine years later, the 71-year-old has run marathons in 48 states.

Wright said he hopes to make New Mexico his 49th state.

“When I run, to be honest, I feel like I’m poking that cancer right in the eye,” Wright said.

So far he has run 69 marathons in 48 states.
Sphincter of Oddi dysfunction http://mouthsofthesouth.com/wp-content/uploads/2016/07/MOTS-08.13.16.pdf cheapest levitra after gallbladder removal including pancreatic disorders. It is a very uncomfortable feeling, and usually occurs due cialis price brand to gastroesophageal reflux disease (GERD). More visitors buying generic viagra translate to more clinking in the empty piggy bank. Hematospermia is viagra online for women a phenomena that the seminal fluid is pink, red, or with a blood clot.
“I’d like people to be healthy and think healthy and if I’m an inspiration, that’s all the better,” Wright said.

He said he wouldn’t been able to run more than a few miles, if not for a special trial cancer drug he began four years ago.

“Which for me has turned out to be a miracle drug. It keeps the cancer stable, it doesn’t cure the cancer but it keeps it at a level where the cancer doesn’t hurt me,” Wright said.

He said he might not ever fully escape his cancer but he’s giving it the race of his life.

“The cancer numbers went down to about one-third of what they were to where it’s safe,” Wright said.

Wright did admit that he’s a little old to be running five or six days a week but he doesn’t plan to stop running marathons.

Wright will take part in the Duke City Marathon on Monday.
He said he plans on running his 50th and final state in Hawaii in December.

After that, he might try Canada.

Posted on

Paralyzed Rats Walk Again After Stem Cell Transplant

Technology Review Published by MIT

http://www.technologyreview.com/view/429222/paralyzed-rats-walk-again-after-stem-cell/

The rodent recovery spurs hope that humans could one day benefit from similar treatments.

Susan Young  <http://www.technologyreview.com/contributor/susan-young/>

Thursday, September 13, 2012

Rats once paralyzed from complete surgical cuts through their spinal cords can walk again after stem cells were transplanted into the site of the injury, report <http://www.sciencedirect.com/science/article/pii/S0092867412010185> researchers today in the journal Cell. The results suggest that stem cells might work as a treatment for patients even if they have completely severed cords, a potential therapy that has been viewed skeptically by many in the
Buying it cialis no prescription from online market will provide you at the lower price. This adds to the effect wholesale cialis price of the capsules. This will permit the hair follicles to online cialis generic be additional open on the blood stream to get the old blood pumping. There are several factors that cause the damage to the penis. order viagra cheap field.

Neural stem cells, derived from aborted fetal spinal cord tissue, were
implanted onto each side of the spinal cord injury in the rats along with a supportive matrix and molecular growth factors. The human stem cells grew into the site of injury and extended delicate cellular projections called axons into the rats spinal cord, despite the known growth-inhibiting environment of the injured spinal cord. The rats’ own neurons sent axons into the transplanted material and the rats were able to move all joints of their hind legs.

The cells are produced by a Rockville, Maryland company called Neuralstem <http://www.neuralstem.com/> . The same cells are also being tested in ALS patients (see “New Cells for ALS Patients
<http://www.technologyreview.com/news/428956/new-cells-for-als-patients/> “) where they have shown some promise of stabilizing the progressive disease. Last month, the company announced
<http://investor.neuralstem.com/phoenix.zhtml?c=203908&p=irol-newsArticle&ID=1463178&highlight> that it has asked to FDA to approve a trial to test the cells in spinal cord-injured patients.

Researchers are currently testing neural stem cells from a Newark,
California-based company called StemCells Inc. <http://www.stemcellsinc.com/> , in spinal cord injured patients; two of the three patients have reported the recover of some sensation (see “Human Stem Cells Found to Restore Memory <http://www.technologyreview.com/news/428532/human-stem-cells-found-to-restore-memory/> ” for an overview of the company).

Posted on

Stem Cells Help Rats Recover Lower-Body Movement

Genetic Engineering & Biotechnology News |
www.genengnews.com

GENNewsHighlights <http://www.genengnews.com/gen-news-highlights/>

Sep 13, 2012

Stem Cells Help Rats Recover Lower-Body Movement

http://www.genengnews.com/gen-news-highlights/stem-cells-help-rats-recover-l
ower-body-movement/81247315/

A half-dozen paraplegic rats recovered movement in all lower joints after being transplanted with <http://www.genengnews.com/keyword/neuralstem/3100> Neuralstem’s <http://www.genengnews.com/keyword/nsi-566/8579>  NSI-566
spinal cord <http://www.genengnews.com/keyword/stem-cells/304>  stem cells-a result the company said could aid in treating human <http://www.genengnews.com/keyword/spinal-cord-injury/692>  spinal cord injury.

The six were among 12 rats experiencing lower-body paralysis after
undergoing complete spinal transections. The six were assessed over seven
weeks and compared to a control group that had not received transplants.
Neuralstem published results of its spinal cord stem cell transplant in the
journal Cell, in a paper titled “Long-Distance Growth and Connectivity of
Neural Stem Cells After Severe Spinal Cord Injury: Cell-Intrinsic Mechanisms
Overcome Spinal Inhibition.”

According to the study, rats treated with NSI-566 showed significant
locomotor recovery, with most (57%) of the grafted cells turned into
neurons. Also significant, according to the company, was the number of axons
that emerged, extending over 17 spinal segments both above and below the
point of spinal cord lesion. The axons expressed synaptic proteins in the
host gray matter, suggesting they made synaptic contact with host spinal
neurons.

“The fact that these cells induce regeneration of axons and partial recovery
of motor function makes them relevant for testing for the treatment of human
spinal cord injury,” Karl Johe, Ph.D., Neuralstem’s chairman and CSO, said
in a statement.

According to the paper, retransecting the spinal cord immediately above the
graft abolished functional gain, a finding that Neuralstem said indicated
that the regeneration of host axons into the human stem cell graft was
responsible for the functional recovery.

Neuralstem has submitted an application to the FDA for a trial to treat
chronic spinal cord injury with NSI-566. The cells were used in a recently
completed Phase I clinical trial for amyotrophic lateral sclerosis (ALS or
Lou Gehrig’s disease).

As blood enters the ventricles, it creates backward pressure that forces the blood to flow into the penis cialis online shop rapidly. This might sound like the best kind of diet, healthy, strong, no side effects and even lead to long lifespan which should be encouraged by viagra brand 100mg the public. As PDE5 is basically spread throughout the body that secrete minute peptides that have instantaneous distal effects buy levitra on line in many other areas. Extra flow of online cialis australia blood to the sexual organs increases the sensitivity and eventually sexual desire.

Posted on

Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats

By Ryan Flinn on September 13, 2012

http://www.businessweek.com/news/2012-09-13/neuralstem-gains-on-stem-cell-therapy-for-paralyzed-rats

Neuralstem rose (CUR) 40 percent to $1.40 at 12:43 p.m. in New York, after earlier increasing as much as 51 percent in its largest intraday gain since Sept. 21, 2009. The Rockville, Maryland-based company’s shares had risen 3.6 percent this year through yesterday.

Prior to captivating this medicine, regard as to cautiously appraise all the feasible dangers and advantages connected with it. discount cialis is the best and most proficient generic key for combating erectile dysfunction. It is a simple, effective way to resolve those tense situations where one child is trying to control or hurt or trespass on another and it is highly, highly effective. http://www.energyhealingforeveryone.com/gcp/GCS.pdf buy cheap cialis “Just walk away.” When a bully tries to steal your child’s emotional well-being, realize that that bully really does not have access to it, your child does. Chiropractic thought is reliant when the relative between the body nervous system and the skeletal online prescription viagra or bone structure. These kinds of cures are the best choices to go with as it comes in three types of consumption like jelly, tablet, and soft tablet and remain demanding medicine by ED men. viagra sales in uk Researchers severed the spinal vertebrae of 12 rats, then gave half of them Neuralstem’s stem cells a week after the injury, according to the study published today in the journal Cell. The rats that received the injections gained “significant locomotor recovery,” according to a company statement.

Neuralstem also is testing its therapy in early human clinical trials for
amyotrophic lateral sclerosis, known as Lou Gehrig’s disease, and for
depression.

Posted on

Advances in regenerative medicine may let patients grow own transplants

Modern medicine:

Advances in regenerative medicine may let patients grow own transplants

http://www.msnbc.msn.com/id/48976348/ns/health-mens_health/

By Maggie Fox

NBC News

A few years ago, Dr. Anthony Atala’s lab at Wake Forest University got good at making ears. They were growing new ears on a scaffold using patient’s cells, because so many soldiers were losing their ears in explosions. Now the Department of Defense has a project that’s closer to Atala’s heart: making new genitals for soldiers who have stepped on bombs.

Other labs are still moving forward with the ear project for the military.  But Atala has special expertise dating back to his days as a pediatric urologist. He’s already grown bladders using a patient’s own cells, and he’s made penises that rabbits were able to put to their proper use, fathering litters of new little bunnies. He hopes to use this expertise to help rebuild the bodies of veterans wounded in Iraq and Afghanistan, as well as men and boys injured in car accidents.

Atala is one of the pioneers of regenerative medicine. But the field has
taken off in a big way, attracting biotechnology companies, the U.S.
military and academic labs, which are working to literally make the blind see and the lame walk again. They’re perfecting spray-on skin and to mass-produce new body parts using bioprinters based on the jet printers attached to your home computer.

“Right now, the way these organs are made is creating them one by one. By bringing the bioprinting in, we can scale it up,” says Atala, whose lab has contracts with the four-year-old Armed Forces Institute of Regenerative Medicine (AFIRM), biotechnology companies and private foundations.

All of this technology is years away from the doctor’s office. The most
advanced treatments have just begun the very earliest stages of human testing. But all evidence points to the tantalizing prospect of
grow-your-own organs and possibly even limbs within a decade or so, and some approaches, such as muscle transplants and spray-on skin, are helping a lucky few now.

Atala’s lab in 2006 made the first full organ ever grown and implanted into a human – the bladder – and the rabbit penises were the first solid organs. A new bid from AFIRM caught his eye. It called for experts in rebuilding the lower abdomen, the genitals, the pelvic area and the bladder.

These injuries are among the least talked-about but among the most horrible affecting war veterans. The improvised explosive devices, or IEDs, planted by insurgents across Iraq and Afghanistan blow off feet, legs and arms, and they can especially damage the pelvic areas that are difficult to protect with body armor.

Atala’s lab is also working to make kidneys, muscle implants, and even to find ways to get fingers to regenerate on their own. (It has to do with waking up some very powerful DNA that goes to sleep soon after a fetus develops). AFIRM’s mission is to align labs like Atala’s with others around the country, getting them to collaborate on projects rather than compete.  AFIRM currently funds around 50 research labs, including leaders such as the University of Pittsburgh Medical Center, Rutgers University, the Cleveland Clinic and Rice University.

“We don’t really feel that other groups are competition at all,” Atala says “Our interest is really to get these technologies into patients. We consider the disease the competition.”

Spray-on skin One area of intense competition – or collaboration – is in spraying on new skin. AFIRM is funding several projects testing a product that uses a patient’s own skin cells, so that rejection is not an issue. Old-fashioned skin grafts may close a wound or a burn, but they don’t heal prettily.  ReCell is a product, more of a process really, that uses a small plug of a patient’s own skin, broken down into a soup using enzymes. Cells known as keratinocytes, which give skin its structure, and the melanocytes, which give color, are pulled out, mixed into a liquid suspension and then sprayed over the damaged area.

It’s a thin layer but the cells quickly multiply and, if the process is done right, form an even layer of new skin within days. The result is much more natural-looking than a graft.

Skin is easier to heal because it’s a relatively simple organ and on the
surface of the body. Limbs are more complicated – they are made up of bone, muscle, nerves, connective tissue and also skin.

Labs are taking a more traditional approach in trying to restore limbs, by transplanting them. But even there regenerative medicine can play a role.  This is where stem cell research comes in. Stem cells are the body’s master cells, and there are several kinds. People have stem cells known as adult stem cells all through their bodies, and they are already partly “educated” to become blood, muscle, bone or nerve cells.

These cells divide and multiply to produce muscle, bones and blood, and they also secrete compounds that help existing tissue and cells regenerate. Some of the projects on AFIRM’s wish list include calls for labs that can combine techniques used to build new body parts with the use of stem cells to help them generate and integrate with the rest of the body.

More powerful cells come from embryos that have barely begun to develop. An entire human body, the collection of muscle, bone, brain, blood, nerves and organs, all develops from the ball of just a few cells that forms days after fertilization. Each one of these cells, known as human embryonic stem cells, contains all the coding needed to make every cell type in the body.
It contains significant amounts of iron, phosphorus, magnesium, manganese, copper and continue reading over here buy levitra in uk zinc. And the male impotence drugs online are 100% natural and are made from herbal extracts, they are much safer, having absolutely zero side effects, unlike prescription medications like cheapest brand cialis . Because the process that causes PVD affects buy viagra discount blood vessels throughout the male body. Do not take more than the prescribed dosage or take it more frequently than once every day, or as regulated by your speordering viagra from india t. if you miss a measurements of this item regardless you aim to take part in sexual action, take it when you recollect.
Helping the blind see In January, scientists at Advanced Cell Technology, a company based in Massachusetts, reported they had used some of these human embryonic stem cells to partially restore vision in two legally blind patients. First they “trained” the cells by incubating them in a nourishing soup of chemicals designed to make them differentiate into retinal cells. The stem cells, infused directly into the eye, regenerated cells known as retinal pigment epithelium cells.

One patient said she can thread needles again and another has been able to resume shopping on her own. ACT has since gotten permission to treat more patients with higher doses of the cells, now that they have at least been shown not to cause any harm. They’re going after patients with degenerative eye diseases such as age-related macular degeneration and Stargardt disease.  In both conditions the cells in the retina gradually die and patients go slowly and irreversibly blind.

They’ve treated 11 more patients, says ACT’s chief medical officer Dr.
Robert Lanza. “In all the patients we have been seeing a very real
biological signal,” Lanza told NBC News. “We have been very pleased because we are talking about very advanced stage patients, and there’s really no treatment for them.”

The experiments, known as clinical trials, are strictly regulated. In the
early stages of human testing, where ACT is now with stem cells, Stage 1 trials recruit only volunteers with advanced, severe disease who have little to lose. The tests are not aimed at showing whether the treatment works, but to ensure that it doesn’t do any harm. Showing efficacy is a big bonus.

“We are far enough along now that we can go into patients with better
vision. That is where we think we will see a very dramatic improvement,” said Lanza.

It doesn’t always go this well. ACT was neck and neck with another company called Geron to be the first to test human embryonic stem cells in people. Geron got there first in 2010, infusing the cells into a young man injured in a car accident, as well as three others. The hope was to regenerate their severed spinal cords. Again, these first patients were treated experimentally only to show the approach was safe and no one dared hope they’d actually improve. And none of them did. Geron dropped its stem cell program in November 2011, saying it wanted to focus on cancer drugs instead.

Lanza said the eyes are a great place to test new treatments because
researchers can literally look in there and see what’s happening. The
spine’s a little harder, but other labs are trying to help there, too.

‘I was afraid it would be a dream’ Ted Harada had a second infusion of stem cells last month. The 40-year-old former Fedex employee has Lou Gehrig’s disease, medically known as amyotrophic lateral sclerosis or ALS. It attacks nerves called motor neurons, gradually and inexorably paralyzing its victims. It’s always fatal as patients lose every bit of their ability to move, even to breathe. There’s no treatment and no cure.

Harada is hopeful enough to have tried the highly experimental treatment not once but twice. It’s painful – surgeons have to cut open his spine and infuse the stem cells right into his spinal fluid. But the last time Harada was treated, he went from walking with a cane to running with his kids – a transformation that made him an instant television celebrity.

“The results I saw were nothing short of miraculous,” says Harada, who lives in Georgia and who got treated at Emory University. “Within two weeks I started feeling my legs getting better. I was afraid it would be a dream and I would wake up and it would be gone again.”

And the effects did gradually wear off, Harada says. “All of a sudden I
started noticing fatigue in my legs,” he told NBC News. “I started noticing trembling, shaking in my legs. If you do a lot of weight lifting you know that rubbery feeling your legs get when they are spent?” That’s how he felt.

In August, Harada got a second infusion of stem cells, which are made by a company called Neuralstem, this time in his neck. “There were a lot of reasons to think this could not safely be done. The spinal cord itself is very precious real estate,” says Dr. Eva Feldman, a neurologist at the University of Michigan who is working on the ALS trial. “You are putting a needle into the spinal cord.”

Feldman admits that researchers on the trial don’t fully understand what the cells are doing. In animals, she says, they form new connections with damaged motor neuron cells in the spine. “They essentially nurture the sick cells into health,” she said. They secrete compounds known as growth factors that nourish the cells in the spinal cord. “They go in there and clean it up so that the whole environment looks less inflammatory … We are not letting the fact that we don’t fully understand how they work prevent us from using
them.”

Harada thinks he may already be feeling something but admits it might be wishful thinking. Trained nurses will measure his muscle strength to see if the new treatment has helped. “I am determined and relentless for them to utilize me as their guinea pig to figure out what is helping me and they can translate this into helping all the other cases of ALS,” says Harada. “I don’t want to provide false hope.”

That’s one thing that worries Dr. Paul Knoepfler, a professor of medicine at the University of California Davis. “There are a lot of clinics sprouting up, offering people stem cell treatment for anything that might be ailing you,” Knoepfler said in a telephone interview. “Some of these pop up in a strip mall, even. They might charge $20,000.”

Yet few, if any, have any real medical credibility, says Knoepfler. “For the most part, the science just isn’t there and yet people are talking about spending a whole chunk of their life savings and the clinic could be totally bogus,” he said.

“We are worried not only for specific patients, but it may tarnish the whole field generally if we have patients getting hurt or even killed by so-called stem cell treatments.”

(c) 2012 NBCNews.com Reprints

Posted on

* Sioux Falls Marathon attracts runners of all ages

KSFY (ABC, Sioux Falls, SD)

Sioux Falls Marathon attracts runners of all ages

http://www.ksfy.com/story/19496437/sioux-falls-marathon-attracts-runners

Posted: Sep 09, 2012 5:35 PM EDT Updated: Sep 09, 2012 7:06 PM EDT

2,000 runners ran a marathon in Sioux Falls today, including Don Wright, 71. He’s running a marathon in each of the 50 states.

He’s a cancer survivor and since his diagnosis 9 years ago, he’s run 66 marathons since being told he had a rare form of blood cancer.

He’s run over 1,500 miles, but he says his biggest complaint in this more than 26 mile race is runner’s knee.

“It’s a goal that keeps me going and it’s important to me and it’s my way of sticking that cancer right in the eye,” Wright said.

Wright is planning to run in Hawaii in December.

He’s also running in Alaska and New Mexico.

He has a blood cancer that affects cells in the bone marrow and can damage bones.
One can visit their super specialty clinic to get rid of orgasm and ejaculatory canadian viagra 100mg issues. The most common side effects of ED generic levitra 5mg medicines include facial flushing, headache, nausea and upset stomach etc. Also buy cialis soft the PDE5 enzyme is the main reason for the diabetes. Erectile dysfunction- disability of maintaining click content now cialis shop sturdy erection is one of the most important parts of males well being when confidence and self-esteem are considered.
It cannot be cured but luckily he can avoid chemo by taking medication and he’s able to train for these marathons.

The Sioux Falls marathon takes dozens and dozens of volunteers to make this marathon happen.

Some runners who took part in the race today came from all over the United States and around the country.

Volunteers tell us they met runners from New York and even Sweden.

“When you can get people from all over the U.S. and other countries it’s definitely going to help and Sioux Falls is a prosperous city. It has shown that with the promotion they have been doing,” Dave Tuch said.

Along with the marathon and half marathon today, there was also the Miracle 5k which raises money for the Children’s Miracle Network at Sanford Children’s Hospital.

The money raised will help sick kids in our area.

Some streets were closed in Sioux Falls because of this marathon.

Downtown street like Phillips Avenue, along with parts of Western Avenue.

Even the on and off ramps of Interstate 229.

Posted on

Neuralstem Showing Promise In Stem Cell Treatment Of ALS

Neuralstem Showing Promise In Stem Cell Treatment Of ALS

by Ramu Iyer

A few days ago, local Fox TV stations aired a story about a medical trial by Neuralstem (CUR), which they described as “one of the most powerful stories we’ve ever reported.” Ted Harada is the eighteenth and final patient to receive human stem cell transplant treatment for amyotrophic lateral sclerosis (ALS) patients as part of a clinical phase 1 trial being conducted at Emory. He is also one of the first patients to ever experience a partial recovery from the dreaded disease. It is also called Lou Gehrig’s disease (the famous sporting star Lou Gehrig died of the disease), and sometimes motor neuron disease, because it is a gradual degeneration of the nerves that control motor functions.  It progressively incapacitates the body’s motor functions to the point where the patient cannot breathe by himself or herself. Up until this point, it has been invariably fatal, with no current treatment or cure. A new stem cell treatment from Neuralstem could change all that.

Neuralstem announced the completion of the phase 1 trial of its NSI-566 spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), with the treatment on Harada. Harada was the third patient to return for an additional set of injections, and phase 1 will conclude six months after this last treatment.  He had his first treatment seventeen months ago when stem cells were transplanted.  Soon he began to get better, and could even walk around the neighborhood with the help of a cane. But recently, the weakness started to come back and Ted volunteered for the second round of treatment.

Neuralstem found out that the fatal nerve damage caused by ALS could be slowed down, and even reversed, by supporting healthy cells in the spinal column with the integration of targeted stem cells.  The stem cells have been cultured and multiplied in their laboratories, and treatment consists of both injecting cells into the spinal cord and exposing the spinal cord to introduce the cells. The stem cells have the capability of growing into nerve cells that support the existing nerves.  You can appreciate the delicacy of the process when you understand that the spinal cord controls every breath you take and every muscle in your body. After completing preliminary studies in animals, the company received FDA approval for human treatment as well as the highly coveted orphan designation. The company developed a patented device for intra-spinal cord surgery, which was used for the stem cell treatment in the eighteen patients. Neuralstem also devised procedures to freeze and preserve the stem cells until they are used.

The purpose of the phase 1 trial was only to assess the safety of the treatment, not to prove the efficacy of benefits. The phase 1 trial commenced in January 2010. The first twelve patients received the treatment in the lumbar or lower back region of the spine.  The treatment was then advanced to the cervical or upper back region. The last three patients received treatment in both regions and the FDA approved the inclusion of previously treated patients in this last batch. The motor neurons that control breathing and the ones that patients need to survive are in the upper spinal cord, primarily in the neck. It is also important to remember that the dosages used in the trial, including the treatment of Ted Harada, were approximately one third of the dosages that will be eventually used.  The trial also meant that patients had to agree to undergo the spinal procedure and to take immuno-suppressant drugs for the rest of their lives in order to prevent rejection of the stem cells being infused.
Mainly, smoking start causing breathing other cheap cialis and cardiac problems, which leads to tiredness and low metabolism, even affecting fertility, together these impact the erection, and men mostly cannot either achieve hard on or sustain it long enough for his or his partner’s needs. Application gels of Sildenafil levitra properien Citrate on the reproductive organ could be some factors for libido loss as well. This infection is often http://www.daveywavey.tv/cialis-7368.html sildenafil india wholesale caused by a tiny bacterium, chlamydia trachomatis. There are many males in the universe who have problem keeping or maintaining erections during the intercourse. pfizer viagra tablets
“There have been many firsts in this trial, including the first lumbar intraspinal injections, the first cervical region intraspinal injections, and the first cohort of patients to receive both,” commented  Jonathan D. Glass, MD, Director of the Emory ALS Center. Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, is the principal investigator on the trial, and an unpaid consultant to Neuralstem. She noted, “We have found the procedure to be extremely safe. In some patients, it appears that the disease is no longer progressing, but it is too early to know if the result from that small number of patients is meaningful.”

Just a few days earlier, Neuralstem announced that it had received a notice of issuance for patent number 12/710,097, titled “Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions.” This patent covers both the culturing of central nervous system cells as well as transplanting them into spinal cord tissue to treat neurodegenerative conditions including ALS. This is an important addition to its intellectual capital, because it covers every stage and facet of the treatment, and the patent is valid up to the year 2030.

In addition to ALS, the company is also targeting other major central nervous system ailments with its treatment such as spinal cord injury and ischemic spastic paraplegia, and has submitted an IND (Investigational New Drug) application to the FDA for a phase 1 safety trial in chronic spinal cord injury. The company is conducting a phase 1b to evaluate the safety of NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD).

This is a promising beginning, but there is still a long way to go before the treatment can be brought to market. This is shaping up to be a promising treatment for a disease previously considered as fatal and untreatable that is going to provide a ray of hope for many patients who may have given up on their condition altogether. While it is still too early to judge whether the treatment is going to be a blockbuster or not, the company is showing great promise. If you are interested in gaining exposure in the biotechnology sector, you should watch this stock carefully for further favorable developments.

Transparency/Disclosure: I am not a registered investment advisor and do not provide specific investment advice. The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research. I am a consultant to a third-party and have received two hundred fifty dollars for independent research. Always discuss investments with a licensed professional advisor before making any financial decisions. Statements made herein are often “forward-looking statements” as stipulated under Section 27A of the Securities Act of 1933, Section 21E of the Securities Act of 1934, and the Private Securities Litigation Reform Act of 1995. While I have researched this company thoroughly, my due diligence is not a substitute for your own.